Clinical activity of single-agent cabozantinib (XL184), a multi-receptor tyrosine kinase inhibitor, in patients with refractory soft tissue sarcomas
2020 ◽
2021 ◽
2004 ◽
Vol 2
(8)
◽
pp. 54-55
2011 ◽
pp. 191-202
◽